A private company called BioVex began Phase I clinical trials for ImmunoVEX, another proposed vaccine, in March 2010.[84] The Company had commenced clinical testing in the UK with its vaccine candidate for the prevention and potentially the treatment of genital herpes. The biopharmaceutical company Amgen bought BioVex[85] and their proposed ImmunoVEX vaccine appears to have been discontinued, furthermore it has been removed from the company's research pipeline.[3]